WO2002074330A3 - Mycobacterrial estracts for treating autoimmune diseases - Google Patents

Mycobacterrial estracts for treating autoimmune diseases Download PDF

Info

Publication number
WO2002074330A3
WO2002074330A3 PCT/GB2002/001323 GB0201323W WO02074330A3 WO 2002074330 A3 WO2002074330 A3 WO 2002074330A3 GB 0201323 W GB0201323 W GB 0201323W WO 02074330 A3 WO02074330 A3 WO 02074330A3
Authority
WO
WIPO (PCT)
Prior art keywords
mycobacterrial
estracts
autoimmune diseases
treating autoimmune
treating
Prior art date
Application number
PCT/GB2002/001323
Other languages
French (fr)
Other versions
WO2002074330A2 (en
Inventor
Graham Arthur William Pro Rook
Laura Cristina Rosa Dr Brunet
Original Assignee
Stanford Rook Ltd
Graham Arthur William Pro Rook
Laura Cristina Rosa Dr Brunet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stanford Rook Ltd, Graham Arthur William Pro Rook, Laura Cristina Rosa Dr Brunet filed Critical Stanford Rook Ltd
Priority to AU2002247836A priority Critical patent/AU2002247836A1/en
Publication of WO2002074330A2 publication Critical patent/WO2002074330A2/en
Publication of WO2002074330A3 publication Critical patent/WO2002074330A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria

Abstract

The present invention relates to mycobacterial extracts comprising lipids, glycolipids and/or carbohydrates and their use in the treatment of autoimmune disease.
PCT/GB2002/001323 2001-03-20 2002-03-20 Mycobacterrial estracts for treating autoimmune diseases WO2002074330A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002247836A AU2002247836A1 (en) 2001-03-20 2002-03-20 Mycobacterrial estracts for treating autoimmune diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0106985.5 2001-03-20
GBGB0106985.5A GB0106985D0 (en) 2001-03-20 2001-03-20 Immunotherapeutic agent

Publications (2)

Publication Number Publication Date
WO2002074330A2 WO2002074330A2 (en) 2002-09-26
WO2002074330A3 true WO2002074330A3 (en) 2003-10-30

Family

ID=9911181

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2002/001323 WO2002074330A2 (en) 2001-03-20 2002-03-20 Mycobacterrial estracts for treating autoimmune diseases

Country Status (3)

Country Link
AU (1) AU2002247836A1 (en)
GB (1) GB0106985D0 (en)
WO (1) WO2002074330A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100992646B1 (en) 2003-07-09 2010-11-05 제이에스알 가부시끼가이샤 Wavelength plate
AP2752A (en) * 2006-11-23 2013-09-30 Cadila Pharmaceuticals Ltd Poly-TLR antagonist
JP2010522155A (en) * 2007-03-20 2010-07-01 カディラ ファーマシューティカルズ リミテッド P38 inhibitor

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4716038A (en) * 1984-04-27 1987-12-29 Stanford John L Methods for the alleviation or treatment of arthritic disease
EP0763361A2 (en) * 1992-02-21 1997-03-19 University College London Mycobacterium vaccae for treatment of long term autoimmune conditions
WO1998039025A2 (en) * 1997-03-03 1998-09-11 Adcock Ingram Limited A composition comprising a carrier and a purified mycobacterial lipid cell-wall component and its use in the prevention, treatment and diagnosis of disease
WO1998043655A1 (en) * 1997-04-02 1998-10-08 Bioniche Inc. Use of bacterial cell wall extracts for treating topical disorders and wounds

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4716038A (en) * 1984-04-27 1987-12-29 Stanford John L Methods for the alleviation or treatment of arthritic disease
EP0763361A2 (en) * 1992-02-21 1997-03-19 University College London Mycobacterium vaccae for treatment of long term autoimmune conditions
WO1998039025A2 (en) * 1997-03-03 1998-09-11 Adcock Ingram Limited A composition comprising a carrier and a purified mycobacterial lipid cell-wall component and its use in the prevention, treatment and diagnosis of disease
WO1998043655A1 (en) * 1997-04-02 1998-10-08 Bioniche Inc. Use of bacterial cell wall extracts for treating topical disorders and wounds

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BARROW WILLIAM W: "Processing of mycobacterial lipids and effects on host responsiveness.", FRONTIERS IN BIOSCIENCE (ONLINE), vol. 2, no. CITED SEPT. 12, 1997, 1997, pages D387 - 400, XP002235435 *
MOURA A C N ET AL: "LIPIDS FROM MYCOBACTERIUM LEPRAE CELL WALL SUPPRESS T-CELL ACTIVATION IN VIVO AND IN VITRO", IMMUNOLOGY, BLACKWELL SCIENTIFIC PUBLICATIONS, GB, vol. 92, no. 4, December 1997 (1997-12-01), pages 429 - 436, XP008014879, ISSN: 0019-2805 *
RABINOVITCH A: "IMMUNOREGULATORY AND CYTOKINE IMBALANCES IN THE PATHOGENESIS OF IDDM THERAPEUTIC INTERVENTION BY IMMUNOSTIMULATION ?", DIABETES, NEW YORK, NY, US, vol. 43, no. 5, May 1994 (1994-05-01), pages 613 - 621, XP001036572, ISSN: 0012-1797 *
RIEDEL D D ET AL: "Differential tolerance induction by lipoarabinomannan and lipopolysaccharide in human macrophages.", MICROBES AND INFECTION / INSTITUT PASTEUR. FRANCE APR 2000, vol. 2, no. 5, April 2000 (2000-04-01), pages 463 - 471, XP002235436, ISSN: 1286-4579 *

Also Published As

Publication number Publication date
AU2002247836A1 (en) 2002-10-03
GB0106985D0 (en) 2001-05-09
WO2002074330A2 (en) 2002-09-26

Similar Documents

Publication Publication Date Title
WO2003057134A3 (en) Specific binding agents of human angiopoietin-2
PL367358A1 (en) Use of flibanserin in the treatment of sexual disorders
EP1767544A3 (en) Methods of treatment of inflammatory diseases using specific binding agents of human angiopoietin - 2
HK1091813A1 (en) 2,4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
WO2003032916A3 (en) Organosulfur inhibitors of tyrosine phosphatases
WO2004087203A3 (en) Immunostimulatory nucleic acid oil-in-water formulations for topical application
WO2005055944A3 (en) Oligosaccharide compositions and use thereof in the treatment of infection
ZA200107315B (en) Pharmaceutical combinations for the treatment of stroke and traumatic brain injury.
HUP0400231A3 (en) Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer
WO2004007743A3 (en) Use of cpg nucleic acids in prion-disease
RS89204A (en) Use of osteoprotegerin for the treatment and/or prevention of fibrotic disease
MXPA03003741A (en) Methods and compositions for the treatment of diseases of the eye.
AUPQ879500A0 (en) Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
MXPA03008634A (en) Novel cyano-substituted dihydropyrimidine compounds and their use to treat diseases.
AU2001268422A1 (en) Agmatine and agmatine analogs in the treatment of epilepsy, seizure, and electroconvulsive disorders
AU2003238242A1 (en) Use of an anti-endotoxin drug in the prevention and treatment of disease
WO2002074330A3 (en) Mycobacterrial estracts for treating autoimmune diseases
AU2002352566A1 (en) Use of corrinoids in the treatment of skin diseases
WO2000078800A3 (en) Combined decorin binding protein and outer surface protein compositions and methods of use
WO2002074333A3 (en) Mycobacterial extracts used for treating allergy
WO2005011728A3 (en) Use of soluble cd164 in inflammatory and/or autoimmune disorders
WO2003013577A3 (en) Use of il-18 inhibitors in hypersensitivity disorders
AU2002221509A1 (en) An chinese medicinal formulation treating stomachache, rib-side pain, headache and menstrual pain
WO2005023288A8 (en) Treatment of fibrotic disease
WO2002030433A3 (en) Use of stem cells and cd6-depleted stem cells for inducing tolerance of allogenic transplants and/or for treating leukaemia

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP